Haleon to acquire the remaining 12% stake in Tianjin TSKF Pharmaceutical for $222m.

Haleon, a British multinational consumer healthcare company, agreed to acquire the remaining 12% stake in Tianjin TSKF Pharmaceutical, a pharmaceutical company, for $222m. The acquisition is expected to be funded through a combination of Haleon's existing cash resources and new third-party Renminbi-denominated debt. Subject to customary closing conditions, including the approval of DRTG's shareholders and applicable regulatory clearances, the transaction is expected to close within the next three months.